Venetoclax for an ATRA and ATO resistance acute promyelocytic leukemia patient with TNRC18::RARA fusion gene

Weina Li; Haijie Li; Xueyan Chen; Yan Zheng

Leukemia Research Reports (Jan 2024)

Venetoclax for an ATRA and ATO resistance acute promyelocytic leukemia patient with TNRC18::RARA fusion gene

Weina Li,
Haijie Li,
Xueyan Chen,
Yan Zheng

Affiliations

Weina Li: Medical Research and Laboratory Diagnostic Center, Jinan Central Hospital, Cheeloo College of Medicine, Shandong University, Jinan, Shandong, PR China
Haijie Li: Department of Cardiac Surgery, Jinan Central Hospital, Affiliated to Shandong First Medical University, PR China
Xueyan Chen: Clinical Laboratory, Department of Clinical Laboratory, The People's Hospital of Longhua Shenzhen, Shenzhen, PR China; Corresponding author: Clinical Laboratory, Department of Clinical Laboratory, The People's Hospital of Longhua Shenzhen, Shenzhen 518109, PR China.
Yan Zheng: Research Center of Translational Medicine, Central Hospital Affiliated to Shandong First Medical University Jinan, Shandong, PR China

Journal volume & issue: Vol. 22
p. 100482

Abstract

Read online

Variant acute promyelocytic leukemia (APL) poses diagnostic and therapeutic challenges primarily because of the absence of PML::RARA. This report presents the case of a patient diagnosed with all-trans retinoic acid (ATRA)-resistant APL harboring the TNRC18::RARA fusion gene. After treatment with venetoclax, azacitidine, and ATRA, the patient achieved complete remission. The patient also developed pulmonary tuberculosis and a multidrug-resistant infection, which improved considerably after antituberculosis treatment and carrimycin, respectively.

Published in Leukemia Research Reports

ISSN: 2213-0489 (Online)
Publisher: Elsevier
Country of publisher: Netherlands
LCC subjects: Medicine: Internal medicine: Neoplasms. Tumors. Oncology. Including cancer and carcinogens
Website: http://www.journals.elsevier.com/leukemia-research-reports/

About the journal

Abstract

Keywords